Published in Head Neck on March 29, 1993
Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas. J Cancer Res Clin Oncol (2009) 0.91
Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes. BMC Cancer (2009) 0.83
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
EBV gene expression in an NPC-related tumour. EMBO J (1989) 2.94
Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med (1990) 2.67
Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol (1990) 2.43
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (1977) 2.07
Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol (1998) 2.03
High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol (1995) 2.00
Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol (1991) 1.91
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs (2000) 1.91
Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol (1998) 1.80
Nasopharyngeal carcinomas: an update. Eur J Cancer (2003) 1.78
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs (1997) 1.53
Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol (1998) 1.52
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol (2004) 1.51
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol (1998) 1.45
Nitrous oxide anesthesia-associated myelopathy. Arch Neurol (2000) 1.40
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol (1999) 1.40
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol (2002) 1.39
Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am (2006) 1.38
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol (2003) 1.36
Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol (2000) 1.35
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol (2001) 1.33
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol (1995) 1.32
Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol (1994) 1.31
Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol (2000) 1.29
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol (1995) 1.28
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol (2001) 1.26
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med (1988) 1.25
The evolution of mature teratoma from malignant testicular tumors. Cancer (1977) 1.24
The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer (1977) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst (1994) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol (1997) 1.18
Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer (1977) 1.16
Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer (2011) 1.15
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol (1996) 1.13
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer (2001) 1.11
Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer (1996) 1.11
cis-Platinum ototoxicity. Clin Toxicol (1978) 1.11
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha. Proc Natl Acad Sci U S A (1987) 1.10
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer (1996) 1.10
Purification and amino-terminal amino acid sequence of an apurinic/apyrimidinic endonuclease from calf thymus. Nucleic Acids Res (1987) 1.10
Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys (1995) 1.10
Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res (1998) 1.10
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol (1992) 1.09
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res (1997) 1.08
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol (2002) 1.07
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer (2006) 1.07
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep (1977) 1.06
Inhibition of cellular mediated immunity in marihuana smokers. Science (1974) 1.05
Sequential bilateral germ cell tumors of the testis despite interval chemotherapy. J Urol (1979) 1.05
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer (2000) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol (2011) 1.04
Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J (1978) 1.04
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol (1998) 1.03
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer (2009) 1.03
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer (1999) 1.03
Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2. J Virol (1989) 1.02
Small-cell carcinoma of the esophagus: treatment by chemotherapy alone. Cancer (1980) 1.01
Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer (1997) 1.00
Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res (1999) 1.00
Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res (1999) 0.99
Neurological complications of malignant germ cell tumors of testis: biology of brain metastases (I). Cancer (1979) 0.99
Measurement of the polarization of W bosons with large transverse momenta in W + jets events at the LHC. Phys Rev Lett (2011) 0.99
Electrochemotherapy on liver tumours in rabbits. Br J Cancer (1998) 0.99
Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int J Cancer (1999) 0.99
Measurement of the inclusive jet cross section in pp collisions at √s = 7 TeV. Phys Rev Lett (2011) 0.98
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer (2009) 0.98
Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J (2000) 0.97
Search for neutral minimal supersymmetric standard model Higgs bosons decaying to tau pairs in pp collisions at √s=7 TeV. Phys Rev Lett (2011) 0.97
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol (1999) 0.97
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol (1997) 0.97
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol (1996) 0.97
High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells. Virology (1997) 0.97
Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer (1990) 0.96